百度试题 结果1 题目日本JALSG AML201研究,患者中位年龄()。相关知识点: 试题来源: 解析 47 反馈 收藏
JALSG AML201 enrolled 1064 previously untreated AML patients (pts) aged 15-64 yrs. The induction therapy consisted of cytarabine (Ara-C 100mg/m2 day1-7) and idarubicin (IDR 12mg/m2 day1-3) (arm A) or cytarabine (100mg/m2 day1-7) and daunorubicin (DNR 50mg/m2......
Clinical Impact of Underweight on the Outcome of Patients with Acute Myeloid Leukemia: Retrospective Study of JALSG AML201In order to investigate better molecular-target therapy for acute myeloid leukemia (AML), we conducted a phase I trial of a combination of gemtuzumab ozogamicin (GO) with ...